Glucotrack Makes Two Senior Appointments

Glucotrack, has appointed John Ballantyne to its Board of Directors, and Sandie Martha as Vice President of Clinical Operations, effective immediately.
 
“We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors,” said Paul Goode, PhD, President and CEO of Glucotrack. “An entrepreneur himself, John brings extensive experience in driving healthcare research and innovation, strategic growth, and other key business functions that will be invaluable as we continue to expand our organization and move towards commercializing our novel technology.”
 
Ballantyne has over 20 years of experience on the executive team at the global biotechnology contract development and manufacturing organization, Aldevron. He co-founded the company in 1998 and served as its Chief Science Officer through its acquisition by Danaher until his retirement. 
 
“I am excited to be joining the Board of such an innovative medical technology company,” said Mr. Ballantyne. “Glucotrack’s continuous blood glucose monitor (CBGM) will really make a difference in the lives of people with diabetes. I look forward to joining the Board and helping the organization to continue to advance its mission, achieve its strategic milestones, and drive toward success.”
 
As VP of Clinical Operations, Martha will be responsible for executing the company’s Clinical Trial Program including strategic partnering with CROs, clinical centers, and investigators, developing and executing clinical protocols, and managing the monitoring and analysis of data for clinical study reports for regulatory agency submissions for the company’s CBGM.
 
“Sandie brings a wealth of knowledge and expertise to the team in leading clinical trials for both glucose monitoring and cardiology,” Goode commented. “The breadth and depth of her experience leading global clinical trials will be invaluable, and we are excited to have her join our team as we embark on Continuous Blood Glucose Monitor (CBGM) human clinical trials to ultimately bring this technology to market for the millions of people living with diabetes.”
 
Martha brings over 20 years of clinical research experience in both medical technology and drug development, leading all aspects of clinical trials including protocol development and execution, clinical site training and monitoring, and regulatory submissions. 
 
She previously served as VP of Clinical Affairs at Glysens, where she led planning and execution for domestic and international clinical trials for an implantable continuous glucose monitor. Her background also includes clinical operations roles in Dexcom, Luminous Medical, and Intersection Medical. Most Recently she served at Truvian, an automated benchtop platform that enables comprehensive routine blood testing. 
 
“Having seen loved ones struggle with their diabetes management, I am passionate about the potential for advanced glucose monitoring technologies. The real-time continuous blood glucose data provided by Glucotrack’s CBGM offers a less intrusive approach to glucose monitoring for extended periods of time, enabling people to live less encumbered by the hassles of traditional glucose monitoring approaches. I am thrilled to join the Glucotrack leadership team in bringing this innovative technology to people with diabetes,” said Martha.